Aardvark Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 |
|---|---|---|
| Revenue | $0 | — |
| Operating income | -$62.7M | -$22.8M |
| Operating expenses | $62.7M | $22.8M |
| Cash from operations | -$54.2M | -$18.1M |
| Capital expenditure | $95,000 | $109,000 |
| Free cash flow | -$54.3M | -$18.2M |
| Total assets | $117.2M | $77.5M |
| Total liabilities | $10.5M | $5.4M |
Shares outstanding 21.8M · Free float 81.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.